List view / Grid view
The antigen-based vaccine has the potential to induce sterilising immunity to old and new SARS-CoV-2 variants by preventing infection by stopping viral replication and transmission through the inhibition of cellular virus entry.
Pre-clinical research from VBI Vaccines has demonstrated an encouraging ability to boost and broaden the immune response against the coronavirus Beta variant.
A monoclonal antibody (mAb) developed by IGM Biosciences to combat COVID-19 has shown success in pre-clinical studies and has now moved into Phase I trials. In this Q&A, Dr Chris Takimoto, Chief Medical Officer at IGM Biosciences, explains how this biotherapeutic works to prevent and treat SARS-CoV-2 infection.
The COVID-19 pandemic has placed a spotlight on the discovery and development of biotherapeutics, for both the treatment and prevention of diseases. In this article, industry experts discuss the emerging trends they see in biotherapeutic development and how they predict the field will evolve in the near future.
Dr John Lewis, CEO of Entos Pharmaceuticals, outlines how an innovative proteolipid platform could enable a new class of DNA-based vaccines in this article.
This ebook includes articles about antibody-based therapies that could protect against cancer by utilising a patient's memory B cells. Also included is a piece on an intranasally-delivered monoclonal antibody treatment to potentially protect against SARS-CoV-2.
In this exclusive piece, Adrien Châtillon, Co-Founder and CEO of Actipulse Neuroscience, explores the future of treatment for diseases that impact mental health.
Researchers from the Technical University of Munich have successfully used specific enzymes to destroy the genetic information of SARS-CoV-2 directly after the virus enters a cell.
Listen to this podcast to discover why mAbs are key in the fight against SARS-CoV-2 and how the pandemic has shaped their development pipeline.
Researchers have made a respiratory model of COVID-19, made from patient-derived stem cells, to understand how the virus affects respiration and which could be used to test possible drugs.
Researchers at UC Davis Health have engineered an antibody that interferes with a critical cell mechanism to reduce transmission of the virus that causes COVID-19 in lab tests.
Using virtual screening, researchers have discovered several natural compounds that could inhibit the SARS-CoV-2 main protease.
Researchers have established a list of compounds that effect cytokine storms that could reduce mortality in COVID-19 patients.
Researchers have found that extracellular vimentin facilitates SARS-CoV-2 entry into human cells, presenting a new target.
Knowledge is power – for scientists at least – and thanks to collaborative research from a UK and German university, we now have better understanding of the SARS-CoV-2 Omicron virus, including how it behaves and effective means of treatment.
